Heptinstall S, Glenn J R, Lösche W, Spangenberg P
Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham, United Kingdom.
Semin Thromb Hemost. 1995;21(2):137-45. doi: 10.1055/s-2007-1000388.
We have investigated the effects of Mg2+ (added to platelet rich plasma [PRP] as 10mM MgCl2 or MgSO4) on the platelet aggregation and actin polymerization that occurs in response to adenosine diphosphate (ADP). The PRP was prepared from blood containing hirudin as anticoagulant. Mg2+ added before 1 microM ADP completely inhibited aggregation and markedly inhibited actin polymerization. Mg2+ (10mM) added before 10 microM ADP converted irreversible aggregation into a reversible response; similarly, apparently irreversible actin polymerization was converted to a reversible response in which polymerization was followed by some actin depolymerization. Mg2+ added after inducing platelet aggregation with 10 microM ADP produced parallel disaggregation of platelets and actin depolymerization. Actin polymerization occurs immediately on adding ADP to PRP (in association with shape change) and further polymerization occurs in association with platelet aggregation. When aggregation (and the actin polymerization associated with this) was prevented by adding M148, a monoclonal antibody directed at the GpIIb/IIIa complex, or simply by avoiding stirring the sample, Mg2+ had no effect on actin polymerization/depolymerization. Thus Mg2+ only affected the changes in actin that were associated with the aggregation response. This was in contrast to iloprost (which acts at the PGI2 receptor to stimulate adenylate cyclase) which induced rapid actin depolymerization when added after ADP stimulation of platelets under circumstances where platelet aggregation was avoided. These results show that Mg2+ affects actin polymerization as well as platelet aggregation, and that it affects the actin polymerization associated with aggregation but not that associated with shape change (in contrast to iloprost which inhibits both).(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了镁离子(以10mM氯化镁或硫酸镁的形式添加到富血小板血浆[PRP]中)对因二磷酸腺苷(ADP)而发生的血小板聚集和肌动蛋白聚合的影响。PRP由含有水蛭素作为抗凝剂的血液制备而成。在1μM ADP之前添加镁离子可完全抑制聚集,并显著抑制肌动蛋白聚合。在10μM ADP之前添加10mM镁离子可将不可逆聚集转变为可逆反应;同样,明显不可逆的肌动蛋白聚合转变为可逆反应,其中聚合之后伴随一些肌动蛋白解聚。在用10μM ADP诱导血小板聚集后添加镁离子,会使血小板平行解聚并使肌动蛋白解聚。向PRP中添加ADP后(与形状改变相关),肌动蛋白立即发生聚合,并且在血小板聚集时进一步发生聚合。当通过添加针对糖蛋白IIb/IIIa复合物的单克隆抗体M148,或简单地避免搅拌样品来阻止聚集(以及与此相关的肌动蛋白聚合)时,镁离子对肌动蛋白聚合/解聚没有影响。因此,镁离子仅影响与聚集反应相关的肌动蛋白变化。这与伊洛前列素(作用于前列环素I2受体以刺激腺苷酸环化酶)相反,在避免血小板聚集的情况下,在ADP刺激血小板后添加伊洛前列素会诱导快速的肌动蛋白解聚。这些结果表明,镁离子影响肌动蛋白聚合以及血小板聚集,并且它影响与聚集相关的肌动蛋白聚合,但不影响与形状改变相关的肌动蛋白聚合(与抑制两者的伊洛前列素相反)。(摘要截短为250字)